Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Develops Therapeutic Drugs To Treat Autoimmune Diseases, And For The Prevention Of Graft Rejection Belonging to the Medical sector which surged 14.02% and closed its last trading session at $3.01.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/11/2016. Currently, the stock has a 1 Year Price Target of $7.5.
The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.
Aurinia Pharmaceuticals Inc. on 6/30/2016 reported its EPS as $-0.1 with the analysts projecting the EPS of the stock as $-0.11. The company beat the analyst EPS Estimate with the difference of $0.01. This shows a surprise factor of 9.1%.
Many analysts have provided their estimated foresights on Aurinia Pharmaceuticals Inc. Earnings, with 4 analysts believing the company would generate an Average Estimate of $-0.14. Whereas they predicted High and Low Earnings Estimate as $-0.12 and $-0.16 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.16.
Analysts are also projecting an Average Revenue Estimate for Aurinia Pharmaceuticals Inc. as $60 Million in the Current Quarter. This estimate is provided by 4 analysts. The High Revenue estimate is predicted as 100 Million, while the Low Revenue Estimate prediction stands at 30 Million. The company’s last year sales total was 57 Million.
The Company got Initiated by H.C. Wainwright on 30-Jun-16 to Buy.
4 analysts projected Price Targets for Aurinia Pharmaceuticals Inc. The analysts believe that the company stock price could grow as high as $10. The Low Price target projection by analysts is $3 and the Mean Price Target is $7.5.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has the market capitalization of $0. The company rocked its 52-Week High of $4.49 on Aug 11, 2016 and touched its 52-Week Low of $1.42 on Jan 15, 2016. The stock has Return on Assets (ROA) of 0 percent. Return on Equity (ROE) stands at 0% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of 21.86 Percent. The company has Beta Value of 0 and ATR value of 0.19. The Weekly and Monthly Volatility stands at 10.07% and 6.38%.
Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.